Hangzhou Alltest Biotech (SH:688606) Xin Lang Cai Jing·2025-10-30 10:24Core Insights - The company reported a revenue of 633 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.44% [1] - The net profit attributable to shareholders was 190 million yuan, showing a year-on-year decline of 3.91% [1] - The basic earnings per share stood at 2.39 yuan [2] Financial Performance - The gross profit margin for the first three quarters was 56.21%, an increase of 0.45 percentage points year-on-year [2] - The net profit margin was 29.97%, a decrease of 2.00 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 55.57%, down 1.52 percentage points year-on-year and down 1.77 percentage points quarter-on-quarter [2] - The net profit margin for Q3 was 28.35%, a decline of 5.06 percentage points year-on-year and a decrease of 3.68 percentage points quarter-on-quarter [2] Expense Analysis - Total operating expenses for the period were 176 million yuan, an increase of 29.15 million yuan year-on-year [2] - The expense ratio was 27.81%, up 4.04 percentage points from the same period last year [2] - Sales expenses increased by 43.00%, management expenses rose by 19.00%, and R&D expenses grew by 3.79% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 5,739, a decrease of 131 from the end of the previous half-year, representing a decline of 2.23% [2] - The average market value per shareholder increased from 907,600 yuan to 952,500 yuan, a growth of 4.95% [2] Company Overview - Hangzhou Aotai Biological Technology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents [3] - The main business revenue composition includes infectious diseases (42.27%), drug and substance abuse (26.74%), and other categories [3] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [3]